Immunocore

Highly Engaged Employees

Immunocore, established in 2008, is a British clinical-stage biotechnology company dedicated to developing innovative biological drugs. Operating within the Biotechnology, Pharmaceuticals, and Healthcare industries, the company utilizes its proprietary soluble T-cell receptor (TCR) technology to create advanced therapies. Immunocore focuses on addressing significant unmet medical needs by developing novel treatments for cancer, infectious diseases, and autoimmune diseases. Learn about Immunocore's global headquarters to understand its operational base in Milton, United Kingdom.

With an employee range of 500-1,000 individuals and operations spanning 3 locations, Immunocore demonstrates substantial operational capacity. The company's product pipeline is built upon its innovative T-cell receptor platform, enabling the development of 'off-the-shelf' biological drugs and therapeutic candidates. These products are designed for precision targeting and delivery, aiming to revolutionize patient treatment paradigms in oncology and other critical disease areas. Meet Immunocore's team to gain insight into the expertise driving these advancements.

Immunocore has secured significant funding, including a $130 million Series B in 2020 and a $75 million Series C in 2021, underscoring investor confidence in its therapeutic approach. The company reported revenue of $400.0M, reflecting its commercial-stage activities and market presence. Its competitive landscape includes other key players in the biopharmaceutical and biotechnology space, such as Adaptimmune Therapeutics and Jazz Pharmaceuticals. Explore financial highlights for a detailed overview of its fiscal performance and investment history.